natgillin/translations-raw huggingface dataset:
To procent af infusionsreaktionerne førte til seponering af behandlingen.
Two percent of the infusion reactions led to discontinuation of treatment.
To randomiserede fase 3-undersøgelser (COMFORT-I og COMFORT-II) blev gennemført med patienter med MF (primær myelofibrose, myelofibrose efter polycythæmia vera eller myelofibrose efter essentiel trombocytose).
Two randomised phase 3 studies (COMFORT-I and COMFORT-II) were conducted in patients with MF (primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis).
To randomiserede, dobbelt-blinde, placebo-kontrollerede undersøgelser (LEVP 2005-1/A og LEVP 2005-1/B) samt data fra to ublindede undersøgelser (LEVP 2006-1 og LEVP 2006-4) viste virkningen af Cinryze til behandling og forebyggelse af angioødem-anfald hos forsøgspersoner med mangel på C1-hæmmer.
Two randomised, double-blind, placebo-controlled studies (LEVP 2005-1/A and LEVP 2005-1/B) and data from two open-label studies (LEVP 2006-1 and LEVP 2006-4) demonstrated the efficacy of Cinryze for the treatment and prevention of angioedema attacks in subjects with C1 inhibitor deficiency.
To randomiserede, dobbeltblinde, multicenter og placebokontrollerede studier er blevet udført på 32 (undersøgelse AC-052-351) og 213 (undersøgelse AC-052-352, BREATHE-1) voksne patienter med WHO funktionsklasse III–IV pulmonal arteriel hypertension (primær pulmonal hypertension eller pulmonal hypertension sekundært til hovedsageligt sklerodermi).
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III– IV pulmonary arterial hypertension (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma).
To randomiserede, dobbeltblinde, multicenter og placebokontrollerede studier er blevet udført på 32 (undersøgelse AC-052-351) og 213 (undersøgelse AC-052-352, BREATHE-1) voksne patienter med WHO funktionsklasse III–IV pulmonal arteriel hypertension (primær pulmonal hypertension eller pulmonal hypertension sekundært til hovedsageligt sklerodermi).
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III–IV pulmonary arterial hypertension (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma).
To randomiserede, dobbeltblinde, placebokontrollerede verifikationsstudier er gennemført i fase III, (MS-F203 og MS-F204).
Two phase III, randomized, double-blind, placebo controlled confirmatory studies, (MS-F203 and MS-F204) have been performed.
To randomiserede, dobbeltblindede, placebokontrollerede, pivotale fase III-studier og et fase II-studie har bidraget til Votubias bivirkningsprofil.
Two randomised, double-blind, placebo-controlled pivotal phase III studies and a phase II study contribute to the safety profile of Votubia.
To randomiserede, fase III, komparative studier med hhv.
Two randomised phase III comparative studies, involving a total of 326 alkylating or
To randomiserede, kontrollerede forebyggelsesstudier blev udført blandt patienter med høj risiko for at udvikle invasive svampeinfektioner.
Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
To randomiserede, kontrollerede forebyggende undersøgelser blev udført blandt patienter med høj risiko for at udvikle invasive svampeinfektioner.
Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
To skemaer til primærvaccination kan anbefales:
Two primary immunisation schedules can be recommended:
To små skåle
Two small bowls
To små skåle (brug et separat sæt skåle til hvert barn)
Two small bowls (use separate pairs of bowls for each child)
To spritservietter
2 alcohol swabs
to spritservietter
two alcohol swabs
to spritservietter
two alcohol swabs,
to spritservietter en fyldt injektionssprøjte indeholdende lægemidlet
two alcohol swabs, one pre-filled syringe containing the medicinal product
To spritservietter til engangsbrug
two alcohol swabs for single use
To sterile 3 ml engangssprøjter af polypropoylen med påsatte kanyler i rustfrit stål.
Two sterile 3 ml disposable polypropylene syringes with stainless steel needles attached.
To sterile sprøjter, den ene med nål til rekonstitution Tre hypodermiske sikkerhedskanyler
Two sterile syringes, one with needle for reconstitution Three hypodermic safety needles
To store fase III-studier blev designet for at undersøge behandlingseffekten af Avastin i kombination med to individuelle kemoterapeutika, målt ved det primære endepunkt progressionsfri overlevelse (PFS).
Two large Phase III trials were designed to investigate the treatment effect of Avastin in combination with two individual chemotherapy agents, as measured by the primary endpoint of PFS.
To store prospektive randomiserede studier, HiLo-studiet (Mallick) og ESTIMABL-studiet (Schlumberger), sammenlignede metoder til ablation af thyroideavæv hos patienter med differentieret thyroideacancer, der havde fået fjernet skjoldbruskkirtlen.
Two large prospective randomised studies, the HiLo study (Mallick) and the ESTIMABL study (Schlumberger), compared methods of thyroid remnant ablation in patients with differentiated thyroid cancer who had been thyroidectomised.
To store randomiserede, kontrollerede studier (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) og VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) har undersøgt samtidig brug af kombinationen af en ACE-hæmmer og en angiotensin-II-receptorblokker.
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
To store randomiserede, kontrollerede studier (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) og VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) har undersøgt samtidig brug af kombinationen af en ACE-hæmmer og en angiotensin-II-receptorblokker.
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) andVA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
To store randomiserede, kontrollerede studier (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) og VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) har undersøgt samtidig brug af kombinationen af en ACE-hæmmer og en angiotensin-II-receptorblokker.
Two large randomised, controlled trials(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
To store undersøgelser med langtidsopfølgning inkluderede 1.071 patienter og 567 patienter efter behandling i tidligere undersøgelser med henholdsvis non-pegyleret interferon alfa-2b (med eller uden ribavirin) og pegyleret interferon alfa-2b (med eller uden ribavirin).
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa- 2b (with or without ribavirin), respectively.
To store undersøgelser med langtidsopfølgning inkluderede 1.071 patienter og 567 patienter efter behandling i tidligere undersøgelser med henholdsvis non-pegyleret interferon alfa-2b (med eller uden ribavirin) og pegyleret interferon alfa-2b (med eller uden ribavirin).
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with nonpegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa-2b (with or without ribavirin), respectively.
to striber i blå tryksværte på hætten og “T 140 mg” i blå tryksværte på bunden
two stripes in blue ink on the cap and “T 140 mg” in blue ink on the body
to striber i grøn tryksværte på hætten og “T 5 mg” i grøn tryksværte på bunden
two stripes in green ink on the cap and “T 5 mg” in green ink on the body
to striber i orange tryksværte på hætten og “T 20 mg” i orange tryksværte på bunden
two stripes in orange ink on the cap and “T 20 mg” in orange ink on the body
to striber i pink tryksværte på hætten og “T 100 mg” i pink tryksværte på bunden
two stripes in pink ink on the cap and “T 100 mg” in pink ink on the body
to striber i rød tryksværte på hætten og “T 180 mg” i rød tryksværte på bunden
two stripes in red ink on the cap and “T 180 mg” in red ink on the body
to striber i sort tryksværte på hætten og “T 250 mg” i sort tryksværte på bunden
two stripes in black ink on the cap and “T 250 mg” in black ink on the body
To studier hos patienter med diabetes blev udført for at vurdere sikkerheden og virkningen af Nevanac 3 mg/ml øjendråber administreret 1 gang dagligt for at forebygge postoperativt makulært ødem efter kataraktoperation.
Two studies in diabetic patients were conducted to assess the efficacy and safety of NEVANAC 3 mg/ml eye drops, suspension dosed once a day for the prevention of postoperative macular oedema associated with cataract surgery.
To sugerør.
Two straws.
To tabletter à 10 mg eller en 20mg tabletén gang dagligt
two 10 mg tablets or one 20 mg tablet once a day
To tabletter à 10 mg én gang dagligt
two 10 mg tablets once a day
To tabletter à 5 mg
Two 5 mg tablets
To tabletter á 10 mg dagligt
Two 10 mg tablets
To tabletter á 10 mg eller én tablet á 20 mg dagligt
Two 10 mg tablets or one 20 mg tablet once a day
to tabletter á 10 mg én gang dagligt
two 10 mg tablets once a day
To til tre timer efter administration lå CSF/plasma ratio af stavudin på mellem 16 – 125% (middel på 59% ± 35%).
Two to three hours post-dose, CSF/plasma ratios of stavudine ranged from 16% to 125% (mean of 59%±35%).
To tilfælde af torsade de pointes er blevet rapporteret i rapporteringsperioden.
During the reporting period, 2 cases of torsade de pointe have been reported.
To tredjedele havde en kompatibel tidslinje og halvdelen af patienterne udviklede svimmelhed indenfor 7 dage efter administration af mirabegron.
Two third had a compatible timeline and half of patients developed dizziness within 7 days of administering mirabegron.
To typer af flerstof resistens mutationer, den første karakteriseret ved mutationer i hiv revers- transkriptase ved codon 62, 75, 77, 116 og 151 og den anden omfatter en T69S-mutation samt en indsætning af 6-base par ved den samme position, hvilket resulterer i en fænotypisk resistens overfor AZT såvel som andre godkendte NRTI’er.
Two patterns of multi-drug resistance mutations, the first characterised by mutations in the HIV reverse transcriptase at codons 62, 75, 77, 116 and 151 and the second involving a T69S mutation plus a 6-base pair insert at the same position, result in phenotypic resistance to AZT as well as to the other approved NRTIs.
To typer af flerstof resistens mutationer, den første karakteriseret ved mutationer i hiv-revers transkriptase ved codon 62, 75, 77, 116 og 151 og den anden omfatter en T69S mutation samt en indsætning af 6-base par ved den samme position, hvilket resulterer i en fænotypisk resistens over for AZT såvel som andre godkendte NRTI’er.
Two patterns of multi-drug resistance mutations, the first characterised by mutations in the HIV reverse transcriptase at codons 62, 75, 77, 116 and 151 and the second involving a T69S mutation plus a 6-base pair insert at the same position, result in phenotypic resistance to AZT as well as to the other approved NRTIs.
To typer pegyleret interferon-alfa (2a og 2b) blev undersøgt i det åbne, randomiserede fase 2a-studie C208 hos behandlingsnaive patienter.
Two types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label, randomised study C208 in treatment-naïve patients.
To ud af tre undersøgte delavirdinresistente, kliniske isolater var krydsresistente over for efavirenz og indeholdt
Two of three delavirdine-resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution.
To ud af tre undersøgte delavirdinresistente, kliniske isolater var krydsresistente over for efavirenz og indeholdt K103N- substitutionen.
Two of three delavirdine- resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution.
To udviklingskar og låg
Two developing tanks and covers
To uger efter administrationen var den maksimale størrelse aftaget til 8 ×4 cm, og der sås en gradvis reduktion af de lokale reaktioner.
By two weeks post administration the maximum size had decreased to 8 x 4 cm, showing a gradual resolution of the local reactions.
To uger efter afslutning af startbehandlingen påbegyndes den anbefalede Vistide- vedligeholdelsesdosis til patienter med normal nyrefunktion på 5 mg pr. kg legemsvægt, der gives 1 gang hver anden uge.
Beginning two weeks after completion of induction treatment, the recommended maintenance dose of Vistide in patients with normal kidney function is 5 mg per kg of body weight given once every two weeks.
To uger efter enhver dosisøgning.
Two weeks after any dose increase.
To uger efter indgrebet skal en topisk kortikosteroid behandling påbegyndes med dexamethason- øjendråber uden konserveringsmiddel 0,1 %, 1 dråbe tre gange om dagen i 2 uger, som dernæst reduceres til 1 dråbe to gange dagligt i 1 uge og 1 dråbe én gang dagligt i yderligere en uge.
Two weeks after surgery, a topical corticosteroid treatment should be started with preservative-free dexamethasone 0.1% eye-drops, 1 drop three times per day for 2 weeks, then reduced to 1 drop twice daily for 1 week and 1 drop once daily for a further week.
To uger senere (Dag 29) fortsættes med en dosis på 40 mg hver uge.
Two weeks later (Day 29) continue with a dose of 40 mg every week.
To undersøgelser med tilsammen 2 257 patienter sammenlignede Aubagio og placebos evne til at mindske antallet af tilbagefald pr. patient pr. år (den årlige tilbagefaldsrate).
Two studies involving 2,257 patients compared the effects of Aubagio with placebo in reducing the number of relapses per patient per year (called the ‘annualised relapse rate’).
To undersøgelser omfattede i alt 699 »behandlingserfarne« patienter, hos hvem den igangværende behandling for hivinfektion ikke havde nogen virkning.
two studies involved a total of 699 ‘treatment-experienced’ patients who were already receiving treatment for HIV infection that was not working.
to undersøgelser, hvori der indgik i alt 1 396 voksne sammenlignede Zinforo med vancomycin og aztreonam, der sammen blev anvendt til behandling af komplicerede infektioner i hud og underliggende væv to undersøgelser, hvori der indgik i alt 1 241 voksne, sammenlignede Zinforo med ceftriaxon ved behandling af samfundserhvervet lungebetændelse. en undersøgelse hvori der indgik 163 børn, sammenlignede Zinforo med vancomycin eller cefazolin, med eller uden aztreonam, til behandling af infektioner i underliggende væv en undersøgelse hvori der indgik 161 børn, sammenlignede Zinforo med ceftriaxon til behandling af samfundserhvervet lungebetændelse, som krævede indlæggelse en undersøgelse hvori der indgik 40 børn sammenlignede Zinforo med ceftriaxon og vancomycin til behandling af kompliceret samfundserhvervet lungebetændelse.
two studies involving a total of 1,396 adults compared Zinforo with vancomycin and aztreonam used together to treat complicated skin and soft tissue infections; two studies involving a total of 1,241 adults compared Zinforo with ceftriaxone to treat community-acquired pneumonia; one study in 163 children compared Zinforo with vancomycin or cefazolin, with or without aztreonam, to treat skin and soft tissue infections; one study in 161 children compared Zinforo with ceftriaxone to treat community-acquired pneumonia that required hospital stay; one study in 40 children finally compared Zinforo with ceftriaxone and vancomycin to treat complicated community-acquired pneumonia.
To vaccinationsprogrammer kan anbefales:
Two immunisation schedules can be recommended:
To virkningsstudier, COMPAS og POET (Pneumococcal Otitis Media Efficacy Trial) blev udført med konjugerede pneumokokvacciner indeholdende protein D: henholdsvis Synforix og en konjugeret 11- valent testvaccine (som yderligere indeholdt serotype 3).
Two efficacy studies, COMPAS and POET (Pneumococcal Otitis Media Efficacy Trial), were conducted with pneumococcal conjugate vaccines containing protein D: Synflorix and an investigational 11-valent conjugate vaccine (which in addition contained serotype 3), respectively.
To yderligere hovedundersøgelserne vedrørte virkningen af Xgeva hos voksne og fuldt udvoksede unge med kæmpecelletumorer i knoglen, der var uegnede til operation, eller hos hvem operation ville medføre svære komplikationer som f.eks. amputation.
Two more main studies looked at the action of Xgeva in adults or full-grown adolescents with giant cell tumour of bone that was unsuitable for surgery or in whom surgery would have resulted in severe complications like amputation of a limb.
To yderligere laboratorieundersøgelser med BTVPUR AlSap 2-4 blev fremlagt som understøttelse for vaccinens virkning.
Two more laboratory studies with BTVPUR AlSap 2-4 were presented to support the efficacy of the vaccine.
To yderligere undersøgelser blev gennemført for at fastsætte beskyttelsesvarigheden for de monovalente vacciner, der hver især indeholder enten bluetongue-virus, serotype 2, eller bluetongue- virus, serotype 4.
Two further studies were conducted to determine the period of protection of the monovalent vaccines each containing either bluetongue virus serotype 2 or 4 respectively.
To-sidet log-rank p-værdic
Two-sided log-rank p-valuec
To-års data fra studie BM 16549
Two year data in study BM 16549
To-års data fra studie BM 16550
Two year data in study BM 16550
TOBI Podhaler 28 mg inhalationspulver, hårde kapsler tobramycin
TOBI Podhaler 28 mg inhalation powder, hard capsules Tobramycin
TOBI Podhaler er indiceret til suppressionsterapi ved kronisk lungeinfektion forårsaget af
TOBI Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to
TOBI Podhaler inhalationspulver, hårde kapsler består af transparente, farveløse, hårde kapsler, som indeholder et hvidt eller næsten hvidt pulver, med “NVR AVCI” trykt i blåt på den ene del af kapslen og Novartis’ logo trykt i blåt på den anden del af kapslen.
TOBI Podhaler inhalation powder, hard capsules consist of a white to almost white powder for inhalation filled into clear colourless hard capsules with “NVR AVCI” imprinted in blue ink on one part of the capsule and the Novartis logo imprinted in blue on the other part of the capsule.
TOBI Podhaler kapslerne må ikke synkes.
Do not swallow TOBI Podhalercapsules.
TOBI Podhaler leveres i månedspakninger, der indeholder 4 ugekartoner og en ekstra Podhaler i opbevaringshylster.
TOBI Podhaler is supplied in monthly packs containing 4 weekly cartons and a reserve Podhaler device in its storage case.
TOBI Podhaler påvirker ikke eller i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
TOBI Podhaler has no or negligible influence on the ability to drive and use machines.
TOBI Podhaler påvirker ikke eller kun i ubetydelig grad arbejdssikkerheden eller evnen til at færdes sikkert i trafikken.
TOBI Podhaler has no or negligible influence on the ability to drive and use machines.
TOBI Podhaler skal tages i cyklusser, hvor 28 dages behandling alternerer med
TOBI Podhaler is taken in alternating cycles of 28 days on treatment followed by
TOBI Podhalers sikkerhed og virkning hos børn under 6 år er ikke klarlagt.
The safety and efficacy of TOBI Podhaler in children aged under 6 years have not been established.
ToC: {DD/MM/YYYY} {hh:mm} {Tidszone}
ToC: {DD/MM/YYYY} {hh:mm}{Time Zone}
ToC: {DD/MM/YYYY}{hh:mm}{Tidszone}
ToC: {DD/MM/YYYY} {hh:mm}{Time Zone}
Toceranib er et lille molekyle, en multikinasehæmmer, som har både direkte anti-tumor-aktivitet og anti-angiogenetisk aktivitet.
Toceranib is a small molecule, multi-kinase inhibitor, that has both direct anti-tumour and anti- angiogenic activity.
Toceranib hæmmede aktiviteten af Flk- 1/KDR tyrosinkinase (vaskulær endotel-vækstfaktorreceptor, VEGFR2), trombocytderiveret vækstfaktorreceptor (PDGFR) og stamcellefaktorreceptor (c-Kit) i både biokemiske og cellulære analyser.
Toceranib inhibited the activity of Flk- 1/KDR tyrosine kinase (vascular endothelial growth factor receptor, VEGFR2), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-Kit) in both biochemical and cellular assays.
Toceranib metaboliseres i leveren og bør anvendes med forsigtighed til hunde, der lider af leversygdomme på grund af manglende studier af virkning ved nedsat nyre- eller leverfunktion,.
Toceranib is metabolised in the liver and in the absence of any studies on the effects of renal or hepatic impairment, should be used with caution in dogs suffering from hepatic disease.
Tocilizumab
All TCZ
Tocilizumab bindes specifikt til både opløselige og membranbundne IL-6 receptorer (sIL-6R og mIL- 6R).
Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R).
Tocilizumab er udviklet til at binde sig til receptoren for et signalmolekyle eller et "cytokin" i kroppen kaldet interleukin-6.
Tocilizumab has been designed to attach to the receptor for a messenger molecule or ‘cytokine’ in the body called interleukin-6.
Tocilizumab SC 162 mg ugentligt + DMARD
TCZ SC 162 mg
Tocilizumabs farmakokinetik blev bestemt ved en populationsfarmakokinetisk analyse af en database, som omfattede -3.552 patienter med reumatoid artrit, som fik 4 eller 8 mg/kg tocilizumab som i.v.- infusion over 1 time hver 4. uge i 24 uger eller 162 mg tocilizumab subkutant enten ugentligt eller hver anden uge i 24 uger.
The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.
Tocilizumabs farmakokinetik blev bestemt ved en populationsfarmakokinetisk analyse af en database, som omfattede 3.552 patienter med reumatoid artrit, som fik af 4 eller 8 mg/kg tocilizumab som i.v.- infusion over 1 time hver 4. uge i 24 uger eller 162 mg tocilizumab subkutant enten ugentligt eller hver anden uge i 24 uger.
The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.
Tocilizumabs farmakokinetik blev bestemt ved en populationsfarmakokinetisk analyse af en database, som omfattede 3.552 RA-patienter behandlet med 162 mg subkutant ugentligt, 162 mg subkutant hver anden uge eller 4 eller 8 mg/kg intravenøst hver 4. uge i 24 uger.
The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with 162 mg subcutaneous every week, 162 mg subcutaneous every other week, and or 4 or 8 mg/kg intravenous every 4 weeks for 24 weeks.
Tocilizumabs farmakokinetiske parametre ændredes ikke over tid.
The pharmacokinetic parameters of tocilizumab did not change with time.
Tocilizumabs sikkerhed hos pJIA-patienter er blevet undersøgt hos 188 patienter i alderen 2 til17 år.
The safety of tocilizumab in pJIA has been studied in 188 patients from 2 to 17 years of age.